Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

viatris gx bv-srl - metoprolol succinate 23,75 mg - eq. metoprolol tartrate 25 mg - prolonged-release tablet - 23,75 mg - metoprolol succinate 23.75 mg - metoprolol

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

recordati ireland ltd. - metoprolol succinate 23,75 mg - prolonged-release tablet - 23,75 mg - metoprolol succinate 23.75 mg - metoprolol

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية العمد - al-amad drug store - nicotine 23.6 mg - 23.6 mg

Canada - English - Health Canada

baxter corporation - sodium chloride - solution - 23.4% - sodium chloride 23.4% - replacement preparations

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - metoprolol succinate 23.75mg; metoprolol succinate 23.75mg; metoprolol succinate 23.75mg - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white 752 active: metoprolol succinate 23.75mg excipient: acetone ethylcellulose glycerol isopropyl alcohol magnesium stearate maize starch methylcellulose microcrystalline cellulose purified water   sepifilm white lp770 - aft - metoprolol is indicated for the following indications: · hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. · angina pectoris. · symptomatic mild to severe chronic heart failure as an adjunct to other heart failure therapy to: increase survival, reduce hospitalisation, improve left ventricular function, improve new york heart association (nyha) functional class and improve quality of life. · cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles. · maintenance treatment after myocardial infarction · hyperthyroidism. · functional heart disorder with palpitations. · migraine prophylaxis.

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - pneumococcal polysaccharides 23 most prevalent types - injection - 25mcg/0.5ml each - pneumococcal polysaccharides 23 most prevalent types 25mcg/0.5ml each

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: hypromellose; microcrystalline cellulose; macrogol 400; ethylcellulose; sodium stearylfumarate; macrogol 6000; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; triacetin - stable, chronic heart failure as an adjunct to other heart failure therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: titanium dioxide; glycerol; magnesium stearate; microcrystalline cellulose; stearic acid; ethylcellulose; maize starch; hypromellose; methylcellulose - stable, chronic heart failure as an adjunct to other heart failure therapy.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

haleon uk ltd - diclofenac diethylammonium - cutaneous gel - 23.2mg/1gram

Australia - English - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - metoprolol succinate, quantity: 23.75 mg - tablet, modified release - excipient ingredients: silicon dioxide; ethylcellulose; hyprolose; microcrystalline cellulose; sodium stearylfumarate; synthetic paraffin; macrogol 6000; hypromellose; titanium dioxide - stable, chronic heart failure as an adjunct to other heart failure therapy.